Anika is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface joint solutions.
Since our incorporation in 1992, Anika has evolved into a market leader in joint preservation. Our comprehensive portfolio of solutions for osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface joint solutions provides expansive treatment options for managing and addressing joint pain across the early intervention continuum of care. Our broad portfolio provides patient care options by managing pain, thus delaying or avoiding a more invasive procedure, and in some cases, slowing the progression of osteoarthritis. With solutions ranging from viscosupplement injections to treat osteoarthritis pain, regenerative solutions that repair damaged tissues, a full complement of sports medicine products, and unique systems for partial or total bone-sparing joint procedures, our focus is to restore active living and help people stay active.
Anika’s culture is defined by its employees who are purpose-driven and passionate about our vision to be a global leader in joint preservation solutions that restore active living for people around the world.
We engage with and invest in each other in a community that values diversity and inclusion.
We strive for the highest quality and compliance in everything
We live up to our promises and do the right thing, every day.
We are agile and entrepreneurial in developing and delivering meaningful solutions.
We operate with mutual respect and trust and are collaborative as we grow together.
We are empowered and accountable to deliver results and value to all our stakeholders.
Our Products and Technology
Osteoarthritis (OA) Pain Management
With over 30 years of global expertise developing, manufacturing and commercializing products based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body and vital for proper joint health and tissue function, we are a leader in viscosupplement injectables for osteoarthritis (OA) pain management. Our key OA pain viscosupplement products include Orthovisc and Monovisc, which are exclusively marketed and sold in the US through the DePuy Synthes division of Johnson and Johnson and outside the US by Anika and our wide network of global commercial partners, and Cingal, an HA-based combination viscosupplement with steroid injectable, currently available in more than 35 countries outside the US through a wide network of global commercial partners. The Cingal pilot study was completely enrolled in the US as of November 2021.
Our portfolio of orthopedic regenerative solutions is driven by our proprietary HA technologies. These products include Tactoset, an HA-enhanced injectable bone void filler designed to treat insufficiency fractures and augment hardware fixation, such as suture anchors, available in the US, and Hyalofast, an off-the-shelf, single stage, HA-based fiber scaffold used to support cartilage regeneration, available in more than 30 countries outside the US.
Arthrosurface Joint Solutions
Anika expanded its portfolio into the joint preservation and restoration space through the acquisition of Arthrosurface in 2020, a company offering minimally invasive partial to total joint replacement implant systems clinically proven to treat patients suffering from arthritis and joint disease. Our uniquely designed anatomic implant systems preserve native joint anatomy across multiple joints, maintain normal biomechanics, require minimal bone removal, and are clinically proven to allow patients to stay active by increasing range of motion and reducing pain.1
Anika further expanded its commitment to the orthopedics space through the acquisition of Parcus Medical in 2020, a company offering a comprehensive range of solutions, including for the repair and reconstruction of soft tissues, commonly used in sports medicine procedures. Our team works diligently with physicians to develop and deliver innovative repair devices that offer healthcare providers compelling options to treat their patients and keep them active.
- Egger AC, Peterson J, Jones MH, Miniaci A. Total shoulder arthroplasty with nonspherical humeral head and inlay glenoid replacement: clinical results comparing concentric and nonconcentric glenoid stages in primary shoulder arthritis. JSES Open Access. 2019 Sep 13;3(3):145-153. doi: 10.1016/j.jses.2019.07.009. PMID: 31709354; PMCID: PMC6834987.